Carboni JM - Search Results

1

BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.

Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, Pollak MN, Gotlieb WH. Beauchamp MC, et al. Among authors: carboni jm. Gynecol Oncol. 2009 Nov;115(2):193-8. doi: 10.1016/j.ygyno.2009.07.009. Epub 2009 Aug 21. Gynecol Oncol. 2009. PMID: 19699512

2

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, Sagar M, Wong TW, Gottardis MM, Erlichman C. Haluska P, et al. Among authors: carboni jm. Mol Cancer Ther. 2008 Sep;7(9):2589-98. doi: 10.1158/1535-7163.MCT-08-0493. Epub 2008 Sep 2. Mol Cancer Ther. 2008. PMID: 18765823 Free PMC article.

3

Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.

Potratz JC, Saunders DN, Wai DH, Ng TL, McKinney SE, Carboni JM, Gottardis MM, Triche TJ, Jürgens H, Pollak MN, Aparicio SA, Sorensen PH. Potratz JC, et al. Among authors: carboni jm. Cancer Res. 2010 Nov 1;70(21):8770-81. doi: 10.1158/0008-5472.CAN-10-1093. Epub 2010 Oct 19. Cancer Res. 2010. PMID: 20959493

4

ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.

Tognon CE, Somasiri AM, Evdokimova VE, Trigo G, Uy EE, Melnyk N, Carboni JM, Gottardis MM, Roskelley CD, Pollak M, Sorensen PH. Tognon CE, et al. Among authors: carboni jm. Cancer Res. 2011 Feb 1;71(3):1060-70. doi: 10.1158/0008-5472.CAN-10-3096. Epub 2010 Dec 9. Cancer Res. 2011. PMID: 21148487

5

Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.

Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten Eyck C, Nakanishi T, Tibodeau JD, Ross DD, Gottardis MM, Erlichman C, Kaufmann SH, Haluska P. Hou X, et al. Among authors: carboni jm. Mol Cancer Ther. 2011 Jan;10(1):117-25. doi: 10.1158/1535-7163.MCT-10-0438. Mol Cancer Ther. 2011. PMID: 21220496 Free PMC article.

6

IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.

Dool CJ, Mashhedi H, Zakikhani M, David S, Zhao Y, Birman E, Carboni JM, Gottardis M, Blouin MJ, Pollak M. Dool CJ, et al. Among authors: carboni jm. Endocr Relat Cancer. 2011 Nov 14;18(6):699-709. doi: 10.1530/ERC-11-0136. Print 2011 Dec. Endocr Relat Cancer. 2011. PMID: 21946410

7

Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, Finckenstein FG, Brodie A, Gottardis MM, Carboni JM, Haluska P. Hou X, et al. Among authors: carboni jm. Cancer Res. 2011 Dec 15;71(24):7597-607. doi: 10.1158/0008-5472.CAN-11-1080. Epub 2011 Oct 31. Cancer Res. 2011. PMID: 22042792 Free PMC article.

8

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE. Law JH, et al. Among authors: carboni j. Cancer Res. 2008 Dec 15;68(24):10238-46. doi: 10.1158/0008-5472.CAN-08-2755. Cancer Res. 2008. PMID: 19074892

9

A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.

Tognon CE, Martin MJ, Moradian A, Trigo G, Rotblat B, Cheng SW, Pollard M, Uy E, Chow C, Carboni JM, Gottardis MM, Pollak M, Morin GB, Sorensen PH. Tognon CE, et al. Among authors: carboni jm. Oncogene. 2012 Mar 8;31(10):1334-40. doi: 10.1038/onc.2011.323. Epub 2011 Aug 1. Oncogene. 2012. PMID: 21804605

10

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M, Erlichman C. Haluska P, et al. Among authors: carboni jm. Cancer Res. 2006 Jan 1;66(1):362-71. doi: 10.1158/0008-5472.CAN-05-1107. Cancer Res. 2006. PMID: 16397250

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67 results

Search Page

Filters